ANNUAL ECONOMIC BURDEN OF STROKE IN PATIENTS WITH TYPE 2 DIABETES IN TURKIYE: A PUBLIC PAYER PERSPECTIVE
Author(s)
Esra SAFAK YILMAZ1, Ceren Simsek, MSc2.
1Healthcare Policies Manager, Novo Nordisk, Ankara, Turkey, 2Istanbul University, Istanbul, Turkey.
1Healthcare Policies Manager, Novo Nordisk, Ankara, Turkey, 2Istanbul University, Istanbul, Turkey.
OBJECTIVES: Stroke is a major diabetes-related complication that requires acute care, follow-up, monitoring, and management of related clinical outcomes. This study aimed to estimate the annual direct medical cost of stroke per-patient with type 2 diabetes in Türkiye and to determine its key drivers from the public payer perspective.
METHODS: A retrospective, micro-costing approach was used to estimate annual per-patient direct medical costs attributable to stroke among patients with type 2 diabetes in Türkiye, from the public payer perspective. Stroke-related resource use across primary, secondary, and tertiary care was defined through prespecified cost domains and informed by estimates from 15 Turkish clinical experts, as no prospective national database routinely captures stroke-related healthcare utilization and costs. Unit costs were derived from the Healthcare Implementation Communiqué (SUT). Cost components included diagnostic testing, outpatient and inpatient care, pharmacological treatment, medical consumables and/or devices, monitoring, adverse events, complications, and inpatient procedures. Annual per-patient costs were calculated by applying unit costs to resource use estimates and summing across all components. The model was externally reviewed by a clinician advisory board.
RESULTS: The estimated annual per-patient direct medical cost attributable to stroke among patients with type 2 diabetes was TRY 18,547, corresponding to US$399 based on the exchange rate applied in the analysis. Pharmacological treatment was the main cost driver, accounting for 35.2% of total costs (TRY 6,537), followed by monitoring tests, which represented 27.8% (TRY 5,153). Together, these two components accounted for approximately two-thirds of the overall annual cost burden. Additional cost contributors included adverse events (TRY 1,952; 10.5%), inpatient procedures (TRY 1,717; 9.3%), and outpatient visits (TRY 1,627; 8.8%).
CONCLUSIONS: Stroke represents a substantial annual direct medical cost burden for the Turkish public payer, with costs driven mainly by pharmacological treatment, monitoring, and management of stroke-related events.
METHODS: A retrospective, micro-costing approach was used to estimate annual per-patient direct medical costs attributable to stroke among patients with type 2 diabetes in Türkiye, from the public payer perspective. Stroke-related resource use across primary, secondary, and tertiary care was defined through prespecified cost domains and informed by estimates from 15 Turkish clinical experts, as no prospective national database routinely captures stroke-related healthcare utilization and costs. Unit costs were derived from the Healthcare Implementation Communiqué (SUT). Cost components included diagnostic testing, outpatient and inpatient care, pharmacological treatment, medical consumables and/or devices, monitoring, adverse events, complications, and inpatient procedures. Annual per-patient costs were calculated by applying unit costs to resource use estimates and summing across all components. The model was externally reviewed by a clinician advisory board.
RESULTS: The estimated annual per-patient direct medical cost attributable to stroke among patients with type 2 diabetes was TRY 18,547, corresponding to US$399 based on the exchange rate applied in the analysis. Pharmacological treatment was the main cost driver, accounting for 35.2% of total costs (TRY 6,537), followed by monitoring tests, which represented 27.8% (TRY 5,153). Together, these two components accounted for approximately two-thirds of the overall annual cost burden. Additional cost contributors included adverse events (TRY 1,952; 10.5%), inpatient procedures (TRY 1,717; 9.3%), and outpatient visits (TRY 1,627; 8.8%).
CONCLUSIONS: Stroke represents a substantial annual direct medical cost burden for the Turkish public payer, with costs driven mainly by pharmacological treatment, monitoring, and management of stroke-related events.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE313
Topic
Clinical Outcomes, Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies, Trial-Based Economic Evaluation
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)